Successful Application of a Virus-Modified Tumor Vaccine for Anti-Metastatic Cancer Immunotherapy

  • V. Schirrmacher
Conference paper


Metastasis is a complex multistep process influenced by tumor cell properties as well as by properties of the host. This is best exemplified with immunological tumor-host interactions. The aim of this presentation is to explore the possibilities of immunological interventions in metastasis. Various approaches have been tried in the past, such as the passive transfusion of monoclonal antibodies or of different types of cells of the immune system, such as NK cells, T cells, LAK cells (lymphokine activated killer cells) or TIL cells (tumor infiltrating lymphocytes). Other approaches aim at nonspecific activation of host defense mechanisms by biological response modifiers (biological or chemical reagents).


Tumor Antigen Newcastle Disease Virus Active Specific Immunotherapy Normal Spleen Cell Active Specific Immunization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Altevogt P, Leidig S, Heckl-Östreicher B (1984) Resistance of metastatic tumor variants to tumor-specific cytotoxic T-lymphocytes not due to defects in expression of restricting major histocompatibility complex molecules in murine cells. Cancer Res 44:5305–5313PubMedGoogle Scholar
  2. Altevogt P, von Hoegen P, Leidig S, Schirrmacher V (1985) Effects of mutagens on the immunogenicity of tumor cells: immunological and biochemical evidence for altered cell surface antigens. Cancer Res 45:4270–4277PubMedGoogle Scholar
  3. Altevogt P, von Hoegen P, Schirrmacher V (1986a) The effects of mutagens on the immunogenicity and antigenicity of murine high and low metastatic lymphomas. Proceedings of the 14th international cancer congress, Budapest, pp 21/27Google Scholar
  4. Altevogt P, von Hoegen P, Schirrmacher V (1986 b) Immunoresistant metastatic tumor variants can reexpress their tumor antigen by treatment with agents that inhibit DNA-methylation. Int J CancerGoogle Scholar
  5. Austin FC, Boone CW (1979) Virus augmentation of the antigenicity of tumor cell extracts. Adv Cancer Res 30:301–345PubMedCrossRefGoogle Scholar
  6. Bosslet K, Schirrmacher V (1981) Escape of metastasizing clonal tumor cell variants from tumor-specific cytolytic T lymphocytes. J Exp Med 154:557–561PubMedCrossRefGoogle Scholar
  7. Bosslet K, Schirrmacher V (1982) High-frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line (ESb). Int J Cancer 29:195–202PubMedCrossRefGoogle Scholar
  8. Bosslet K, Schirrmacher V, Shantz G (1979) Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. Similar specificity patterns of protective anti-tumor immunity in vivo. Int J Cancer 24:303–313PubMedCrossRefGoogle Scholar
  9. Cassel WA, Garret RE (1965) Newcastle Disease Virus as an anti-neoplastic agent. Cancer 18:863PubMedCrossRefGoogle Scholar
  10. Kerbel RS, Man MS, Dexter D (1984) A model of human cancer metastasis: extensive spontaneous and artificial metastasis of a human pigmented melanoma and derived variant sublines in nude mice. J Natl Cancer Inst 72:93–108PubMedGoogle Scholar
  11. Kobayashi H (1979) Viral xenogenization of intact tumor cells. Adv Cancer Res 30:279–299PubMedCrossRefGoogle Scholar
  12. Kramer MD, Robinson P, Vlodavsky I, Barz D, Friberger P, Fuks Z, Schirrmacher V (1985) Characterization of an extracellular matrix-degrading protease derived from a highly metastatic tumor cell line. Eur J Cancer Clin Oncol 21:307–316PubMedCrossRefGoogle Scholar
  13. Larizza L, Schirrmacher V, Pflüger E (1984a) Acquisition of high metastatic capacity after in vitro fusion of a nonmetastatic tumor line with a bone-marrow derived macrophage. J Exp Med 160:1579–1584PubMedCrossRefGoogle Scholar
  14. Larizza L, Schirrmacher V, Graf L, Pflüger E, Peres-Martinez M, Stöhr M (1984 b) Suggestive evidence that the highly metastatic variant ESb of the T-cell lymphoma Eb is derived from spontaneous fusion with a host macrophage. Int J Cancer 34:699–707PubMedCrossRefGoogle Scholar
  15. North RJ (1985) Down-regulation of the antitumor immune response. Adv Cancer Res 45:1–42PubMedCrossRefGoogle Scholar
  16. Schirrmacher V (1979) Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. V. Transfer of protective immunity with H-2 identical immune T cells from B 10.D2 mice. Int J Cancer 24:80–86PubMedCrossRefGoogle Scholar
  17. Schirrmacher V (1980) Commentary. Shifts in tumor cell phenotypes induced by signals from the microenvironment: relevance for the immunobiology of cancer metastasis. Immunobiology 157:89–98PubMedCrossRefGoogle Scholar
  18. Schirrmacher V (1985) Cancer metastasis: experimental approaches, theoretical concepts and impacts for treatment strategies. Adv Cancer Res 43:1–73PubMedCrossRefGoogle Scholar
  19. Schirrmacher V, Shantz G, Clauer K, Komitowski D, Zimmermann H-P, Lohmann-Matthes ML (1979a) Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastases formation in vivo. Int J Cancer 23:233–244PubMedCrossRefGoogle Scholar
  20. Schirrmacher V, Bosslet K, Shantz G, Clauer K, Hübsch D (1979b) Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between the parental tumor line and its metastasizing variant. Int J Cancer 23:245–252PubMedCrossRefGoogle Scholar
  21. Schirrmacher V, Bosslet K, Altevogt P, Rußmann E, Beck L, Fogel M (1982a) Microenvironmental influences on tumor-host interactions studies with high and low metastatic tumor lines. Tumor progression and markers. Proceedings IV. meeting of EACR, Budapest 1981, Kugler, Amsterdam, pp 155–164Google Scholar
  22. Schirrmacher V, Fogel M, Russmann E, Bosslet K, Altevogt P, Beck L (1982b) Antigenic variation in cancer metastasis. Immune escape versus immune control. Cancer Metastasis Rev 1:241–274PubMedCrossRefGoogle Scholar
  23. Schirrmacher V, von Hoegen P, Heicappell R, Altevogt P (1986a) Modulations of tumor cell immunogenicity leading to increased T cell reactivity and decreased metastasis formation. In: Herberman RB, Wiltrout R, Gorelik E (eds) Immune responses to metastases. CRC Press, Boca RatonGoogle Scholar
  24. Schirrmacher V, Braun M, Waller CA, Benke R, Larizza L (1986b) Changes in adhesive, invasive and metastatic capacity of a T lymphoma after fusion with a bone marrow derived macrophage. In: Macher E, Sorg C (eds) Local immunity in cancer. Reyen and Biermann, pp 72–83Google Scholar
  25. Schirrmacher V, Ahlert T, Heicappell R, Appelhans B, von Hoegen P (1986c) Successful application of non-oncogenic viruses for anti-metastatic cancer immunotherapy. Cancer RevGoogle Scholar
  26. Storch E, Kirchner H, Schirrmacher V (1986) Prolonged survival of mice against the Eb and ESb lymphoma by treatment with interferon inducers alone or in combination with Corynebacterium parvum. Cancer Immunol ImmunotherGoogle Scholar
  27. Vlodavsky I, Schirrmacher V, Ariav Y, Fuks Z (1983a) Lymphoma cell interaction with cultured vascular endothelial cells and with the subendothelial basal lamina: attachment, invasion and morphological appearance. Invasion Metastasis 3:81–97PubMedGoogle Scholar
  28. Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirrmacher V (1983b) Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. Cancer Res 43:2704–2711PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • V. Schirrmacher

There are no affiliations available

Personalised recommendations